RxSight, Inc. $RXST Stock Holdings Boosted by Voya Investment Management LLC

Voya Investment Management LLC grew its position in shares of RxSight, Inc. (NASDAQ:RXST) by 247.6% during the 3rd quarter, Holdings Channel reports. The firm owned 94,063 shares of the company’s stock after purchasing an additional 66,999 shares during the period. Voya Investment Management LLC’s holdings in RxSight were worth $846,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of RXST. Petrus Trust Company LTA boosted its stake in RxSight by 5.0% during the first quarter. Petrus Trust Company LTA now owns 19,651 shares of the company’s stock valued at $496,000 after buying an additional 938 shares in the last quarter. State of Wyoming lifted its holdings in RxSight by 91.5% in the 1st quarter. State of Wyoming now owns 2,062 shares of the company’s stock valued at $52,000 after acquiring an additional 985 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of RxSight by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock valued at $552,000 after purchasing an additional 1,232 shares in the last quarter. Legal & General Group Plc boosted its position in shares of RxSight by 5.0% during the 2nd quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock valued at $579,000 after purchasing an additional 2,121 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of RxSight in the 2nd quarter worth approximately $28,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

RXST has been the subject of several recent research reports. Zacks Research raised shares of RxSight from a “strong sell” rating to a “hold” rating in a research note on Monday, September 8th. Morgan Stanley upped their price target on RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Stifel Nicolaus set a $10.00 price objective on RxSight in a research report on Thursday, November 6th. Needham & Company LLC raised their price objective on RxSight from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RxSight in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, RxSight currently has a consensus rating of “Reduce” and a consensus price target of $9.67.

RxSight Stock Performance

RxSight stock opened at $10.42 on Thursday. The company has a 50 day moving average price of $10.64 and a 200 day moving average price of $9.77. RxSight, Inc. has a 52 week low of $6.32 and a 52 week high of $37.13. The firm has a market capitalization of $428.47 million, a price-to-earnings ratio of -11.84 and a beta of 1.14.

RxSight (NASDAQ:RXST) last announced its earnings results on Wednesday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.15. The company had revenue of $30.34 million for the quarter, compared to the consensus estimate of $25.63 million. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. The company’s revenue was down 31.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) EPS. Equities analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

RxSight Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.